{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:40:13Z","timestamp":1787647213551,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,9,16]],"date-time":"2011-09-16T00:00:00Z","timestamp":1316131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1245\/s10434-011-2065-9","type":"journal-article","created":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T20:42:04Z","timestamp":1316119324000},"page":"1466-1471","source":"Crossref","is-referenced-by-count":15,"title":["Cinacalcet (Sensipar) Provides no Measurable Clinical Benefits for Patients with Primary Hyperparathyroidism and may Accelerate Bone Loss with Prolonged Use"],"prefix":"10.1245","volume":"19","author":[{"given":"James","family":"Norman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Politz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,16]]},"reference":[{"key":"2065_CR1","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","volume":"95","author":"EF Nemeth","year":"1998","unstructured":"Nemeth EF, Steffry ME, Hammerland, LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998;95:4040\u20135.","journal-title":"Proc Natl Acad Sci USA."},{"key":"2065_CR2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","volume":"48","author":"D Padhi","year":"2009","unstructured":"Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48:303\u201311.","journal-title":"Clin Pharmacokinet."},{"key":"2065_CR3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1043-2760(98)00119-2","volume":"10","author":"EF Nemeth","year":"1999","unstructured":"Nemeth EF, Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab. 1999;10:66\u201371.","journal-title":"Trends Endocrinol Metab."},{"key":"2065_CR4","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/ndt\/gfp144","volume":"24","author":"P Urena","year":"2009","unstructured":"Urena P, Jacobson SH, Vervloet M, et al. Cinacalcet and achievement of the NKF\/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice\u2014the ECHO observational study. Nephrol Dial Transplant. 2009;24:2852\u20139.","journal-title":"Nephrol Dial Transplant."},{"key":"2065_CR5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/039139880903200208","volume":"32","author":"J Bover","year":"2009","unstructured":"Bover J, Aguilar A, Baas J, et al. Calcimimetics in the chronic kidney disease-mineral and bone disorder. Int J Artif Organs. 2009;32:108\u201321.","journal-title":"Int J Artif Organs."},{"key":"2065_CR6","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","volume":"88","author":"DM Shoback","year":"2003","unstructured":"Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. JCEM. 2003;88:5644\u20139.","journal-title":"JCEM."},{"key":"2065_CR7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","volume":"90","author":"M Peacock","year":"2005","unstructured":"Peacock M, Bilezikian JP, Klassen PS, Gou MD, Turner SA, Shoback D. Cinacalcet HCL maintains long-term normocalcemia in patients with primary hyperparathyroidism. JCEM. 2005;90:135\u201341.","journal-title":"JCEM."},{"key":"2065_CR8","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","volume":"94","author":"C Marcocci","year":"2009","unstructured":"Marcocci C, Chanson P, Shoback D, Bilezikian J, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. JCEM. 2009;94:2766\u201372.","journal-title":"JCEM."},{"key":"2065_CR9","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","volume":"94","author":"M Peacock","year":"2009","unstructured":"Peacock M, Bolognese M, Borfsky M, Scumpia S, Sterling LR, Cheng S, Shoback D. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. JCEM. 2009;94:4860\u20137.","journal-title":"JCEM."},{"issue":"1","key":"2065_CR10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jamcollsurg.2010.03.019","volume":"211","author":"M Vasher","year":"2010","unstructured":"Vasher M, Goodman A, Politz D, Norman J. Postoperative calcium requirements in 6000 patients undergoing outpatient parathyroidectomy: easily avoiding symptomatic hypocalcemia. J Am Coll Surg. 2010;211(1):49\u201354.","journal-title":"J Am Coll Surg"},{"issue":"33","key":"2065_CR11","first-page":"147","volume":"2008","author":"J Norman","year":"8000","unstructured":"Norman J, Politz D. Measuring individual parathyroid gland hormone production in real-time during radioguided parathyroidectomy. Experience in over 8000 operations. Minerva Endocrinol. 2008,33;147\u201357.","journal-title":"Minerva Endocrinol."},{"key":"2065_CR12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4158\/EP09346.OR","volume":"17","author":"J Norman","year":"2011","unstructured":"Norman J, Goodman A, Politz D. Calcium, parathyroid hormone, and vitamin D in patients with primary hyperparathyroidism: normograms developed from 10,000 cases. Endocr Pract. 2011;17:384\u201394.","journal-title":"Endocr Pract."},{"issue":"3","key":"2065_CR13","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1245\/s10434-008-0276-5","volume":"16","author":"J Norman","year":"2009","unstructured":"Norman J, Politz D. 5000 parathyroid operations without frozen section or PTH assays: measuring individual parathyroid gland hormone production in real-time. Ann Surg Oncol. 2009;16(3):656\u201366.","journal-title":"Ann Surg Oncol"},{"key":"2065_CR14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.endonu.2010.09.009","volume":"58","author":"A Arranz Martin","year":"2011","unstructured":"Arranz Martin A, Villalon AA, Ramirez ML, et al. Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery. Endocrinol Nutr. 2011;58:24\u201331.","journal-title":"Endocrinol Nutr."},{"issue":"1","key":"2065_CR15","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1210\/jc.2010-1221","volume":"96","author":"M Peacock","year":"2011","unstructured":"Peacock M, Bilezikian JP, Bolognese MA, et al. Cinacalcet HCL reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab. 2011;96(1):E9\u201318.","journal-title":"J Clin Endocrinol Metab"},{"key":"2065_CR16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.metabol.2007.11.014","volume":"57","author":"S Sajid-Crockett","year":"2008","unstructured":"Sajid-Crockett S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism. 2008;57:517\u201321.","journal-title":"Metabolism."},{"key":"2065_CR17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000323902","volume":"34","author":"J Henschkowski","year":"2011","unstructured":"Henschkowski J, Bischoff-Ferrari HA, Wuthrich RP, Serra AL. Renal function in patients treated with cinacalcet for persistent hyperparathyroidism after kidney transplantation. Kidney Blood Press Res. 2011;34:97\u2013103.","journal-title":"Kidney Blood Press Res."},{"key":"2065_CR18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1159\/000304180","volume":"31","author":"KA Borchhardt","year":"2010","unstructured":"Borchhardt KA, Diarra D, Sulsbacher I, Benesch T, Haas M, Sunder-Plassmann G. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol. 2010;31:482\u20139.","journal-title":"Am J Nephrol."},{"key":"2065_CR19","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1016\/j.transproceed.2010.09.059","volume":"42","author":"S Borstnar","year":"2010","unstructured":"Borstnar S, Erzen B, Gmeiner ST, Kocjan T, Arnol M, Kandus A, Kovac D. Treatment of hyperparathyroidism with cinacalcet in kidney transplant recipients. Transpl Proc. 2010;42:4078\u201382.","journal-title":"Transpl Proc."},{"key":"2065_CR20","doi-asserted-by":"crossref","first-page":"F1315","DOI":"10.1152\/ajprenal.00552.2009","volume":"298","author":"JL Finch","year":"2010","unstructured":"Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, Slatopolsky E. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol. 2010;298:F1315\u201322.","journal-title":"Am J Physiol Renal Physiol."},{"key":"2065_CR21","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.surg.2010.09.009","volume":"148","author":"R Schneider","year":"2010","unstructured":"Schneider R, Kolios G, Koch BM, Fernandez ED, Bartsch DK, Schlosser K. An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism\u2014the German perspective. Surgery. 2010;148:1091\u20139.","journal-title":"Surgery."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-011-2065-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-011-2065-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-011-2065-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T20:25:26Z","timestamp":1592943926000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-011-2065-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,16]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["2065"],"URL":"https:\/\/doi.org\/10.1245\/s10434-011-2065-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,16]]}}}